Browse Careers
Browse Investors

Bard Reports Third Quarter Results

Murray Hill, NJ -- October 17, 2001 -- C. R. Bard, Inc. (NYSE-BCR) today reported net sales of $297.8 million for the quarter ended September 30, 2001, up 8 percent over prior year's net sales of $275.4 million. Adjusting for the negative effect of currency translation, third quarter net sales would have increased by 10 percent. Net income for the third quarter was $35.7 million, and diluted earnings per share was 68 cents, up 5 percent and 3 percent, respectively, over the same period in the prior year. In the prior-year period, Bard reported net income of $34.0 million and diluted earnings per share of 66 cents, which included legal settlements and a gain from asset dispositions amounting to $4.1 million or 4 cents diluted earnings per share after tax. Excluding these one-time items in the prior-year period, net income and diluted earnings per share would have increased 12 percent and 10 percent, respectively.

William H. Longfield, chairman and chief executive officer, commented, "Bard's third quarter sales growth of 10 percent, on a constant currency basis, demonstrates the continued strength of the company's core franchises. We are pleased by this performance and look forward to building further on our positive momentum."

Third quarter net sales in the U.S. were $218.2 million, up 10 percent over the prior-year period, and net sales outside the U.S. were $79.6 million, up 3 percent over the same period in the prior-year. Adjusting for the negative currency translation effect, net sales growth outside the U.S. would have increased by 8 percent in the third quarter and 7 percent for the first nine months of the year 2001.

In addition, the company said that it remains comfortable with its full-year 2001 diluted earnings per share estimate of $2.75, consistent with previous guidance.

C. R. Bard, Inc., (www.crbard.com) headquartered in Murray Hill, New Jersey, is a leading multinational developer, manufacturer and marketer of health care products in the fields of vascular, urology, oncology and surgical specialty products.

This press release contains forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. Please refer to our June30, 2001 Form 10-Q for a statement with regard to forward-looking statements, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied.

C.R. Bard, Inc.
Consolidated Statements of Income


(thousands of dollars except per share amounts,

unaudited)



  Quarter Ended
September 30,
  Nine Months Ended
September 30,
 
 
  2001   2000   2001   2000
 
 
 
 
 
Net Sales $297,800   $275,400   $878,500   $818,500
 
Costs and expenses:  
  Cost of goods sold 139,500   126,100   410,200   370,900
  Marketing, selling & administrative 91,200   87,900   272,300   261,800
  Research & development expense 13,100   13,000   40,300   40,700
  Interest expense 3,500   4,900   11,200   15,400
  Gain from dispositions of cardiology business 0   0   0   (15,400)
  Other (income) expense, net (1) (700)   (5,800)   (4,100)   1,900
 
 
 
 
Total costs and expenses 246,600   226,100   729,900   675,300
 
 
 
 
 
Income before taxes 51,200   49,300   148,600   143,200
  Income tax provision 15,500   15,300   44,700   44,600
 
 
 
 
 
Net income $ 35,700   $ 34,000   $103,900   $ 98,600
 
 
 
 
 
Basic earnings per share $     0.70   $     0.67   $     2.04   $     1.95
 
 
 
 
 
Diluted earnings per share $     0.68   $     0.66   $     2.01   $     1.93
 
 
 
 
 
Average common shares outstanding-basic 51,324   50,767   50,966   50,648
 
Average common shares outstanding-diluted 52,276   51,324   51,669   51,169
 
 
(1) In addition to interest income and foreign exchange, other (income)

expense, net for the third quarter of 2000 includes a net pretax gain of $4,100 ($.04 diluted per share after-tax) resulting

from asset dispositions and legal settlements.



Product Group Summary of Net Sales

  Quarter Ended September 30,   Nine Months Ended September 30,
  2001   2000   Change   Constant
Currency
  2001   2000   Change   Constant
Currency
 
 
 
 
 
 
 
 
Vascular $62,600   $59,100   6%   10%   $185,700   $181,100   3%   6%
Urology 100,000     91,300   10%   11%     291,300     269,000   8%   10%
Oncology   70,700     65,300   8%   9%     204,000     187,100   9%   10%
Surgery   49,700     44,900   11%   11%     151,900     135,300   12%   13%
Other   14,800     14,800   0%   -3%       45,600       46,000   -1%   -1%
 
 
         
 
       
Total net sales $297,800   $275,400   8%   10%   $878,500   $818,500   7%   9%
 
 
         
 
       


bard-pubs

Primary Media Relations Contact

Scott Lowry
Vice President and Treasurer
C. R. Bard, Inc.
730 Central Avenue
Murray Hill, NJ 07974

Tel: 908-277-8365